Videos

Shuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.

David G. Maloney, MD, PhD, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor T-cell therapy to patients receiving treatment in the outpatient setting.

Michael J. Mauro, MD, discusses the unmet needs of patients with chronic myeloid leukemia and what potential therapies are being investigated currently for this patient population.

Carlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.

Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.

Joshua Brody, MD, discusses how he sees the use of immunotherapy evolving in coming years.

Mustafa Khasraw, MD, discusses a follow-up trial to the VERTU study for patient with methylated or unmethylated MGMT glioblastoma who responded well to temozolomide chemotherapy and radiation.

Nancy Lin, MD, discusses options for patients with human epidermal growth factor receptor 2-positive breast cancer who also present with brain metastases.

Sonali M. Smith, MD, discusses the current understanding of mantle cell lymphoma and how this understanding has evolved over recent years to understand different subsets of the disease that may require different frontline treatment for patients.

Ragini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.

Shaji K. Kumar, MD, discusses how patients with multiple myeloma respond to different types of therapy.

Michael R. Charlton, MD, MBBS, discusses different types of therapy and trials in the hepatocellular carcinoma setting right now.